Cardio3 BioSciences appoints Dr Atta Behfar
pharmafile | July 29, 2010 | Appointment | Research and Development | Cardio3, appointment, research and development
Belgium biotech company Cardio3 BioSciences has appointed Dr Atta Behfar as director for advanced research.
He will spend a year at the company, joining its research and development operations while on assignment from US healthcare institute the Mayo Clinic.
Dr Behfar was a member of the Mayo Clinic’s clinician investigator programme in cardiology and played a key role in the research underlying Cardio3 BioSciences’ lead product, C-Cure, a stem cell treatment for heart failure.
He said: “It is a very exciting time for Cardio3 BioSciences with C-Cure having shown encouraging early results in a clinical setting. I look forward to working with the in-house team as they further advance the product from being a scientific concept towards becoming a therapy that could potentially treat one of the world’s greatest unmet medical needs.
“Many additional treatments may also be leveraged out of the science that lead to C-Cure discovery, and my role will be to fully develop the potential of Cardio3 BioSciences’ unique technology.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






